Don A. Gabriel, MD, PhD.

Sr. Director, Medical Oncology and Scientific Strategy

Don A. Gabriel, MD, PhD, joined UBC as Sr. Director, Medical Oncology and Scientific Strategy in 2015. In this role, Dr. Gabriel will support our operational team and support staff on oncology and medical issues and training. Dr. Gabriel was a Professor of Medicine at the University of North Carolina (UNC) at Chapel Hill, where he was a bone marrow transplant physician. He has previously served as Associate Chief of Staff, Assistant Dean for Clinical Services, Acting Chief of Medical Oncology, and Service Chief Liaison of the Division of Hematology/Oncology at UNC. His areas of expertise include oncology, hematology, and the application of physical methods such as light scattering to hemostasis, hematology and oncology. He has also served on NIH and FDA study sections and served on an IRB committee.

Dr. Gabriel completed an internal medicine residency at Massachusetts General Hospital and a Fellowship in Hematology at UNC. He is recognized as a leader in the fields of hematology and oncology, and is a recipient of the Lineberger Cancer Center Distinguished Achievement Award. Dr. Gabriel has served as co- or principal investigator on more than 100 clinical trials. He has published more than 250 research papers and abstracts and presented more than 400 invited lectures. He has served as an authority on oncology-focused topics such as chemotherapy-induced oral mucositis in bone marrow transplantation and hemostasis. Additionally, Dr. Gabriel has authored oncology books and chapters, a Dover monograph on laser light scattering theory and has presented numerous research papers at national and international forums. Lecture topics include a wide range of topics such as coagulation complications of cancer, intravenous therapies, multiple myeloma treatment and the use of various physical instrumentation such as light scattering in clinical medicine.

In addition, Dr. Gabriel has served as a clinical consultant to many leading pharmaceutical companies and is a founder of Invitrox, where he serves as President and Chairman of the Board of Directors. There, he is focused on the development of cell-based assays for diagnostic purposes and drug monitoring.

Dr. Annette Stemhagen

Chief Science Officer

Annette Stemhagen, DrPH, FISPE is an epidemiologist with more than 35 years of public health research experience, including epidemiologic research and safety surveillance of pharmaceutical and biotechnology products, vaccines, and medical devices. She provides strategic consultative services with a focus on risk evaluation and mitigation strategies (REMS) and developing real-world evidence to meet regulatory and commercial objectives regarding product safety and value.

Dr. Stemhagen has specific expertise in the design, implementation, and analysis of epidemiologic studies, both observational and pragmatic, for products in Phase IIIb and post-approval. She has designed and evaluated risk assessment studies, including more than 60 regulatory-mandated, long-term global safety studies. She has also designed global risk minimization programs and risk management evaluation studies and developed REMS for more than 120 products.

Dr. Stemhagen is active in the International Society for Pharmacoepidemiology and the Drug Information Association. She served on the Board of Directors for each of these organizations. Dr. Stemhagen has held adjunct faculty appointments at the University of Pennsylvania Center for Epidemiology and Biostatistics in the School of Medicine, the Temple University School of Pharmacy, and the Drexel University School of Public Health. Dr. Stemhagen was appointed as the first Industry Representative to the FDA Drug Safety and Risk Management Advisory Committee.  In addition to providing consultative services, Dr. Stemhagen has held positions within the government, academia, and the pharmaceutical industry focused on patient safety.